Improved outcomes in metastatic colorectal cancer are allowing patients to consider periods of reducedintensity chemotherapy, however real-world use of these modifications is poorly described. In this population-based cohort, 39% of patients used either intermittent or maintenance chemotherapy during treatment and modifications were associated with improved outcomes, suggesting physicians can appropriately select patients who are safe to undergo treatment modifications. Background: With improved survival and longer duration of treatment, clinicians managing metastatic colorectal cancer (mCRC) increasingly consider intermittent (IC) or maintenance chemotherapy (MC), but the effect of these treatment modifications on real-world outcomes is unclear. Patients and Methods: Using a population-based cohort of mCRC patients who received combination chemotherapy, we aimed to describe the use of IC/MC and their effect on overall survival (OS). Results: Among 617 patients, 120 (19%) had periods of IC, 67 (11%) had periods of MC, and 53 (9%) had periods of both. Most (85.5%) modifications occurred in the first-line setting. The receipt of IC (median OS [mOS], 37 vs. 21 months; P < .0001) or MC (mOS, 36 vs. 24 months; P ¼ .0015) was associated with improved mOS compared with continuous combination therapy. In multivariate analysis adjusting for age, sex, and regimen used at the time of treatment modification, IC (hazard ratio [HR], 0.52; 95% confidence interval [CI], 0.42-0.65; P < .0001), MC (HR, 0.71; 95% CI, 0.58-0.88; P ¼ .002), and the combination (HR, 0.45; 95% CI, 0.33-0.63; P < .0001) were all associated with improved mOS. Among patients receiving MC, individuals with (HR, 0.69; 95% CI, 0.53-0.90; P ¼ .005) and without (HR, 0.74; 95% CI, 0.55-1.00; P ¼ .048) re-escalation to their original cytotoxic regimen had improved mOS compared with continuous therapy. The use of IC was associated with an improved OS compared with MC (HR, 0.65; 95% CI, 0.47-0.90; P ¼ .009). Conclusion: In patients with mCRC, IC and MC are reasonable options to maintain quality of life and do not appear to negatively affect OS in carefully selected patients.
Introduction
The incorporation of novel agents into the treatment of metastatic colorectal cancer (mCRC) has resulted in improved outcomes, with median overall survival (mOS) exceeding 30 months in recent trials. 1 With these advances, patients are being exposed to chemotherapy for longer periods of time. As a result, strategies that maintain quality of life (QoL) are increasingly considered during treatment planning. The 2 major strategies ( Figure 1 ) considered include complete treatment holidays with intermittent chemotherapy or periods of maintenance chemotherapy with omission of oxaliplatin/irinotecan and continuation of a fluoropyrimidine with or without a biologic.
Intermittent chemotherapy was first assessed in the United Kingdom Medical Research Council Colorectal 06 (UK MRC CR06) trial, which evaluated treatment breaks for patients with responding or stable disease after 12 weeks of 5-fluorouracil. They demonstrated similar overall survival (OS; hazard ratio [HR] , 0.87; 95% confidence interval [CI] , 0.69-1.09; P ¼ .23), no difference in 1 use of second-line chemotherapy, and fewer side effects for patients who received intermittent compared with continuous treatment. 2 Intermittent 5-fluorouracil plus irinotecan (FOLFIRI) administered on a 2-month on/2-month off schedule was also shown to result in similar progression-free survival (PFS; HR, 1.03; 95% CI, 0.81-1.29) and OS (HR, 0.88; 95% CI, 0.69-1.14) compared with continuous therapy in the Group for the Study of Gastrointestinal Cancer (GISCAD) trial, whereas the Medical Research Council COIN (MRC COIN) trial failed to meet its noninferiority criteria for intermittent 5-fluorouracil plus oxaliplatin (FOLFOX) (OS HR, 1.084; 95% CI, 0.97-1.21; PFS HR, 1.052; 95% CI, 0.95-1.17). 3, 4 The use of maintenance chemotherapy was subsequently proposed as a means of providing disease suppression during periods of less intensive therapy. When first evaluated in optimize oxaliplatin 1 (OPTIMOX1), maintenance 5-fluorouracil after a 6-cycle FOLFOX induction resulted in similar PFS (HR, 1.06; 95% CI, 0.89-1.20; P ¼ .47) and OS (HR, 0.93; 95% CI, 0.72-1.11; P ¼ .49) compared with continuous FOLFOX. 5 Bevacizumab has also been evaluated in the maintenance setting in the Spanish Cooperative Group for the Treatment of Digestive Tumours (MACRO TTD) as well as Swiss Group for Clinical Cancer Research 41/06 (SAKK 41/06) trials; however, neither trial showed benefit to bevacizumab maintenance. 6, 7 The optimize oxaliplatin 2 (OPTIMOX2) as well as Dutch Colorectal Cancer Group 3 (CAIRO3) attempted to evaluate whether maintenance or intermittent chemotherapy resulted in improved outcomes. OPTIMOX2 randomized patients to 6 cycles of modified 5-fluorouracil plus oxaliplatin followed by maintenance 5-fluorouracil or a complete stop to chemotherapy. Single-agent fluoropyrimidine maintenance improved duration of disease control (HR, 0.71; 95% CI, 0.51-0.99; P ¼ .046) compared with intermittent chemotherapy. 8 Similarly, CAIRO3 showed that a fluoropyrimidine with bevacizumab improved time to second PFS (HR, 0.67; 95% CI, 0.56-0.81; P < .0001). 1, 9 This strategy of a fluoropyrimidine combined with bevacizumab after induction has become one of the most widely used approaches for de-escalation and is currently highlighted by the 2016 European Society for Medical Oncology guidelines for such patients. 1 Although maintenance therapy appears to result in improved PFS compared with intermittent chemotherapy, both strategies are important options for patients. A major concern with incorporating the evidence from the previously mentioned trials into practice is that the trials had rigid frameworks that required patients to receive a certain number of cycles before de-escalation and did not allow a mixture of intermittent and maintenance chemotherapy. With this in mind, we aimed to determine: (1) the real-world frequency of intermittent and maintenance chemotherapy; (2) whether these strategies result as detriment to survival; and (3) if there are any predictors of which patients will undergo treatment modification. To answer these questions, we evaluated patient records and tumor registry data of a population-based cohort from the British Columbia Cancer Agency (BCCA) who were newly diagnosed with mCRC and started a doublet chemotherapy regimen with or without a biologic between 2008 and 2010.
Patients and Methods

Description of the Study Setting
The BCCA is a province-wide cancer agency that provides publicly funded cancer care to 4.7 million people in British Columbia, Canada. It 
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Maintenance/Intermittent Chemotherapy and Survival in mCRC consists of 6 cancer centers that provide a full range of oncologic care. The BCCA Gastrointestinal Cancer Outcomes Unit (GICOU) prospectively collects demographic, disease, treatment, and outcome-related data on all patients referred to the BCCA and uses physician follow-up as well as government vital statistics for survival ascertainment.
Patient Population
After obtaining approval from the institutional review board, the GICOU database at the BCCA was queried for all patients diagnosed with mCRC between January 1, 2008 and December 31, 2010 in the province. The time frame of the cohort was chosen to allow 5 years of follow-up for all patients. We identified 1249 patients who had not received previous systemic therapy in the metastatic setting. Individuals diagnosed with previous malignancies except nonmelanoma skin cancers within the past 5 years were excluded, as were patients who were treated with < 2 cycles of chemotherapy, single-agent (cytotoxic) chemotherapy, curative-intent resection of metastases, or radiotherapy. We limited our analysis to patients who received combination chemotherapy to ensure patients were eligible for either intermittent or maintenance strategies.
Pharmacy records were searched for all chemotherapy prescriptions to determine whether patients received either intermittent or maintenance chemotherapy. The BCCA pharmacy is responsible for distributing oral and intravenous chemotherapy agents to all patients treated within the BCCA and thus provides comprehensive records of drug administration without concern that patients might have received an agent from an outside pharmacy.
Definitions of Treatment Strategies and Key Variables
Intermittent chemotherapy was defined as a treatment break of 45 days without any cytotoxic agent followed by resumption of the same regimen. Treatment modifications were assessed in all lines of therapy. Maintenance chemotherapy was defined as the omission 1 cytotoxic agent in a patient previously treated with combination therapy for 1 cycle. Because of the retrospective nature of this study, it was difficult to reliably ascertain whether an intermittent or maintenance treatment strategy was adopted because of toxicity. As a proxy, we assessed whether patients underwent reinitiation of an omitted agent because patients who stopped a drug because of toxicity are less likely to resume the same drug. Staging was on the basis of the American Joint Committee on Cancer sixth edition staging manual. 10 Tumors were considered left-sided if the primary was located from the splenic flexure to the rectum. In te rm itte n t C h e m o M a i n t e n a n c e a n d In te rm itte n t P< .0 0 0 1 S u rv iv a l (M o n th s ) P e rc e n t s u rv iv a l 
Maintenance/Intermittent Chemotherapy and Survival in mCRC
Variables remained in the model if their P value was < .1. The use of concurrent bevacizumab or anti-epidermal growth factor receptor directed therapy was not assessed. All variables satisfied the proportional hazards assumption. Logistic regression modeling was performed to assess whether any baseline characteristics were predictive of treatment modifications. Variables assessed include age, sex, sidedness of primary, and treatment regimen. Variables were selected with a forward LR method and remained in the model if their P value was < .1. A complete case approach was used in multivariate analysis. A 2-sided P value of < .05 was considered significant. Analysis was performed with GraphPad Prism version 5 (GraphPad Software, Inc) and SPSS version 14.0 (SPSS, Inc). In te rm itte n t C h e m o M a i n t e n a n c e a n d In te rm itte n t P <.0 0 0 1 
S u rv iv a l (M o n th s ) P e rc e n t s u rv iv a l
Results
Baseline Characteristics
Of 1249 patients diagnosed with mCRC at the BCCA between 2008 and 2010, 617 (49.4%) met inclusion criteria and were eligible for analysis of treatment de-escalation. Of those, 120 (19.4%) had 1 episode of intermittent chemotherapy, 67 (10.9%) had 1 period of maintenance, and 53 (8.6%) had periods of both. Median time without chemotherapy for patients who received intermittent chemotherapy was 81 days (interquartile range, 56-157 days). Most (85.5%) modifications occurred in the first-line setting. For patients who received maintenance chemotherapy, 68 (56.7%) had reinitiation of the omitted agent. As shown in Table 1 , there was no difference in age, sex, first treatment regimen, or sidedness of primary between groups, but there were trends toward a larger proportion of rectal cancer patients using intermittent chemotherapy compared with other modifications (P ¼ .067).
Survival Analysis
The mOS of patients who had a period of intermittent (HR, 0.53; 95% CI, 0.44-0.64; P < .0001) or maintenance chemotherapy (HR, 0.62; 95% CI, 0.51-0.75; P < .0001) was significantly longer than for patients who received continuous combination therapy. mOS of patients receiving intermittent, maintenance, and continuous combination therapy was 40, 36, and 20 months, respectively. With maintenance therapy, the mOS did not differ between patients who had reinitiation of the omitted agent compared with those who did not (HR, 0.88; 95% CI, 0.19-1.56; P ¼ .63), and both groups appeared to have improved mOS compared with patients who received continuous chemotherapy (P < .0001). Receipt of intermittent chemotherapy was associated with an improvement in mOS compared with maintenance (HR, 0.63; 95% CI, 0.44-0.89; P ¼ .0088), whereas patients who received episodes of both appeared to have the best mOS of all groups (P < .0001). In a sensitivity analysis that excluded all patients who received < 3 months of their first-line therapy before changing to a second-line regimen, we noted that all findings remained statistically significant between treatment groups (Figures 2 and 3 ).
Multivariate Model
Cox proportional hazards models were created to compare all potential treatment modifications and control for covariates. Results are summarized in Table 2 . Only treatment modification and sidedness of the primary were significant variables. Right-sided tumors were associated with a worse outcome in all models (HR ranged from 1.65 to 1.67).
Model 1 compared all possible treatment modifications and showed that patient receipt of intermittent (HR, 0.53; 95% CI, 0.42-0.65; P < .0001), maintenance (HR, 0.72; 95% CI, 0.55-0.95; P ¼ .02), or both modifications (HR, 0.47; 95% CI, 0.35-0.63; P < .0001) was associated with improved OS compared with continuous combination chemotherapy. In model 2, we assessed whether patients who received maintenance had different outcomes depending on whether they had reinitiation of the omitted agent. Those with (HR, 0.69; 95% CI, 0.53-0.90; P ¼ .005) as well as those without re-escalation (HR, 0.74; 95% CI, 0.55-1.00; P ¼ .048) had an associated improvement in OS compared with patients who received continuous combination therapy. In model 3 we directly compared intermittent with maintenance therapy and noted that intermittent chemotherapy was associated with improved OS (HR, 0.65; 95% CI, 0.47-0.90; P ¼ .009).
Predictors of Modification
Logistic regression showed that age, sex, sidedness of primary, and chemotherapeutic regimen were not predictive for either intermittent chemotherapy or maintenance chemotherapy. Although neither treatment with capecitabine plus oxaliplatin nor capecitabine plus irinotecan before maintenance chemotherapy were associated with reescalation, the use of any capecitabine regimen was associated with a higher probability of re-escalation (HR, 5.91; 95% CI, 1.27-27.5; P ¼ .024).
Discussion
Our results show that real-world use of treatment de-escalation is common, with almost 40% of mCRC patients undergoing either intermittent or maintenance chemotherapy. De-escalation was associated with improved OS, suggesting that these modifications do not result in inferior outcomes among carefully selected patients. Previous evidence supporting modified treatment strategies is mostly derived from prospective trials. Strict inclusion criteria and rigid protocols in trials frequently mandate a set treatment induction period before deescalation, which might make the results less generalizable to a general oncology population for whom treatment is usually more flexible. Our work is an important addition to the literature because it supports de-escalation strategies in a population-based cohort of patients and shows that clinicians can carefully select patients to undergo deescalation without compromising outcomes.
Interestingly, we did not identify any clinical predictors of treatment de-escalation, most likely because of our limited power and sample size. Another reason might be homogeneity of patient treatment. At the BCCA, most patients receive FOLFIRI first-line because of its perceived better tolerability. Because de-escalation was more frequent in the first-line setting, this might explain why oxaliplatin was not predictive of de-escalation despite its potential to cause neuropathy. Because FOLFOX was usually reserved for the second-line setting in which treatment modifications were less prevalent, oxaliplatin was not observed to correlate with de-escalation. Of note, we observed that capecitabine-based regimens had an association with re-escalation. The small number of patients in this subgroup makes it difficult to draw conclusions about this finding, but oral drugs might lend themselves to re-escalation because of their convenience of administration.
A key difference between our results and most previous studies was the improvement in OS with intermittent chemotherapy compared with maintenance. OPTIMOX2, CAIRO3, and AIO-027 all showed that maintenance therapy results in improved disease control whereas a metaanalysis by Berry et al showed no detriment to intermittent therapy. 8, 9, 11, 12 Our finding is an important consideration because intermittent chemotherapy allows patients greater flexibility and might be associated with improved QoL. In CAIRO3 there were improvements in global QoL and mean fatigue for patients who received intermittent treatment, but the QoL survey scores were not of a magnitude that would suggest clinical significance. 9 Similarly, MRC COIN showed that intermittent chemotherapy resulted in improved social (odds ratio [OR], 0.82; 95% CI, 0.70-0.96; P ¼ .016) and role functioning (OR, 0.82; 95% CI, 0.70-0.96; P ¼ .015) compared with single-agent fluoropyrimidine. 3 The preferential use of intermittent over maintenance therapy might also have economic advantages for patients and health care systems trying to manage rising costs. Part of the reason we noted improved outcomes with intermittent compared with maintenance strategies might have been that some patients in the maintenance arm likely had one of their agents discontinued because of toxicity. These patients might be at increased risk of a negative outcome because the modification was unplanned. In total, 43.3% of patients who received maintenance did not have re-escalation. We tried to assess whether discontinuation without reinitiation might affect OS as a surrogate for discontinuation because of toxicity because agents discontinued because of toxicity would be less likely to be reinitiated. There was no difference in outcomes between those who had re-escalation versus those who did not, suggesting there was little difference between patients who had maintenance chemotherapy because of toxicity versus other reasons. Another potential explanation for the difference in outcomes might have been physician preference to use complete chemotherapy-free periods in only patients with the best disease control, but we were unable to retrospectively assess this.
The survival analysis from our study must be interpreted with caution because of the significant selection bias present in patient group assignment. We tried to control for bias in patient selection by performing a sensitivity analysis that eliminated all patients who received < 3 months of first-line systemic therapy before changing to their second-line regimen, however, there is still inherent bias in our analysis. Physicians likely only offered de-escalation to patients with good initial response to upfront therapy or those with low burden of disease. The difference between our retrospective population and that of clinical trials is a strength as well as a weakness. There are likely many real-world patients who do not have a depth of response that would warrant de-escalation after a set number of cycles or who might never attain significant disease control. Thus, it would not be reasonable for these patients to undergo de-escalation as might be mandated by trials. In our population in which we observed a significant improvement in OS with de-escalation, it is likely attributed to clinicians and their ability to select patients who would tolerate maintenance or intermittent therapy. Because of the bias inherent to retrospective studies, our results do not imply that de-escalation has a causal role in improving outcomes. Conversely, the findings suggest that clinicians should be assured that some patients are able to pursue de-escalation without experiencing compromised outcomes. This information might be very helpful during discussions with patients. Ultimately, the decision as to whether treatment de-escalation should be attempted must be on the basis of patient priorities and physician judgement.
Conclusion
The use of treatment de-escalation in mCRC is prevalent and these modifications do not appear to result in inferior outcomes. Clinician judgement appears to be a reasonable method of assessment of which patients will have good outcomes with de-escalation.
Clinical Practice Points
During the treatment of mCRC, patients who achieve a response to therapy can consider periods of reduced-intensity chemotherapy with either maintenance or intermittent chemotherapy as strategies to improve QoL. Clinical trials have shown that intermittent as well as maintenance chemotherapy can be delivered safely, however, real world uptake of these strategies is not well described and the effect of patient selection for a dosing modification has not been assessed but might have important implications for patient outcomes. The trials that assessed these dosing strategies followed rigid
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Clinical Colorectal Cancer March 2018 -71 frameworks regarding the timing of a modification that often do not reflect the practicalities of a patient's life. In this population-based cohort, we showed that 39% of patients will undergo some form of dosing modification during their treatment and patients who undergo a modification have improved outcomes. Intermittent chemotherapy was actually associated with improved outcomes compared with maintenance chemotherapy, which is contrary to the results suggested by prospective trials. These results suggest that physicians are able to appropriately select patients who can undergo a treatment de-escalation safely and that intermittent as well as maintenance chemotherapy are important treatment options for patients with mCRC.
